The therapeutic potential of interleukin-6 in treating obesity
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)-6 is a multifunctional immune-modulating cytokine that has been suggested to have important functions in glucose and lipid metabolism. It is secreted from adipose tissue during resting conditions and from muscle during strenuous exercise. Recently, the authors reported that mice deficient of IL-6 develop mature-onset obesity, which was reversed by IL-6 replacement. The IL-6-deficient mice had increased glucose levels and decreased glucose tolerance, and blood lipids were increased in females. Furthermore, it was found that intracerebroventricular (ICV) IL-6 treatment acutely increased energy expenditure in rats and led to loss of fat mass following prolonged treatment, without causing symptoms of sickness behaviour or increased levels of acute-phase reactants. Thus, these data indicate a role for IL-6 in the regulation of energy homeostasis in rodents. In humans, several single nucleotide polymorphisms in the IL-6 gene promoter are known, one of which (174 C) is associated with reduced IL-6 transcription as well as decreased basal metabolic rate and insulin sensitivity in healthy male subjects. Furthermore, it was found that IL-6 levels in cerebrospinal fluid in obese humans were inversely correlated with more severe obesity, suggesting that severe obesity is coupled to a relative central IL-6 deficiency. Taken together, these data suggest that endogenous IL-6 has antiobesity effects and, therefore, it is possible that low endogenous IL-6 production contributes to obesity in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V, Yudkin, J. S., Humphries, S., & Woo, P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2629 · Cited by 2,243 · cited 2×
“This study showed lower insulin sensitivity in subjects with the weak -174 C/C IL-6 promoter polymorphism in comparison with subjects with the -174 G/G polymorphism, which is a stronger inducer of IL-6 gene transcription [66].”
BackgroundResultInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 1×
“Intracellular signal transducers for IL-6 include the Janus kinase (Jak 1, 2 and Tyk 2) and signal transducer and activator of transcription (STAT3 and, less so, STAT1) pathways [10,11].”
BackgroundVan Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890 · cited 1×
“IL-6 elicits pro-inflammatory effects, including induction of the acute-phase reaction and transformation of B lymphocytes to antibody-producing plasma cells [10,21].”
BackgroundImpaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“In one of the first articles describing IL-6 knockout mice, Kopf and co-workers showed that endogenous IL-6 is essential for the immune response to certain intracellular pathogens, such as Listeria monocytogenes, and viruses, for example, vaccinia [22].”
BackgroundLiver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538 · cited 1×
“Besides its effects on immune and metabolic functions, IL-6 has an established role in stimulation of liver regeneration after partial hepatectomy [37,38], and it is one of the few known hormonal regulators of intact liver size in rodents [39].”
BackgroundInterleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 10×
“(2003) 3(7) body fat and energy expenditure [7,20,48,49], it was of interest to study the correlation between IL-6 levels in the cerebrospinal fluid (CSF) and obesity in humans.”
BackgroundResultInfluentialSelf-citationCaro, J. F., Kolaczynski, J. W., Nyce, M. R., Ohannesian, J. P., Opentanova, I., Goldman, W. H., Lynn, R. B., Zhang, P.-L., Sinha, M. K., & Considine, R. V. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03173-x · Cited by 1,175 · cited 1×
“In contrast, CSF leptin levels correlated positively with body weight, subcutaneous and total body fat, in line with earlier results [70,71].”
ResultCerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans
Schwartz, M. W., Peskind, E., Raskind, M., Boyko, E. J., & Porte, D. (1996) · Nature Medicine · doi:10.1038/nm0596-589 · Cited by 1,014 · cited 1×
“In contrast, CSF leptin levels correlated positively with body weight, subcutaneous and total body fat, in line with earlier results [70,71].”
ResultPro‐ and anti‐inflammatory cytokine balance in strenuous exercise in humans
Ostrowski, K., Rohde, T., Asp, S., Schjerling, P., & Pedersen, B. K. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.287ad.x · Cited by 1,014 · cited 1×
“Circulating levels of IL-6, but not TNF-α and IL-1β, increase prominently (up to 100-fold) during exercise, reflecting increased expression of IL-6 mRNA in skeletal muscle in the absence of muscle damage [32,33].”
BackgroundVgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Kales, A., Tyson, K., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3950 · Cited by 974 · cited 4×
“Not surprisingly, the levels of IL-6 correlate positively with body mass index (BMI) [4,28] in a similar way as shown for leptin [42].”
BackgroundInfluentialInsulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Fernández-Real, J. M., & Ricart, W. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0010 · Cited by 886
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“Other results suggesting that IL-6 may be diabetogenic came from the finding that IL-6 could inhibit the effect of insulin in hepatocytes [60], and that IL-6 inhibited expression of the insulin sensitising hormone adiponectin in cultured adipocyte-like 3T3 cells and adipose tissue cultures [61,62].”
BackgroundExercise and IL‐6 infusion inhibit endotoxin‐induced TNF‐α production in humans
Starkie, R., Ostrowski, S. R., Jauffred, S., Febbraio, M., & Pedersen, B. K. (2003) · The FASEB Journal · doi:10.1096/fj.02-0670fje · Cited by 790 · cited 1×
“A similar inhibitory effect of IL-6 on endotoxin-induced TNF-α release was recently shown in humans during exercise and IL-6 infusion [24].”
BackgroundInterleukin 6 and its receptor: ten years later
Hirano, T. (1998) · International Reviews of Immunology · doi:10.3109/08830189809042997 · Cited by 788 · cited 3×
“Intracellular signal transducers for IL-6 include the Janus kinase (Jak 1, 2 and Tyk 2) and signal transducer and activator of transcription (STAT3 and, less so, STAT1) pathways [10,11].”
BackgroundInterleukin-6 stimulates lipolysis and fat oxidation in humans
van Hall, G., Steensberg, A., Sacchetti, M., Fischer, C., Keller, C., Schjerling, P., Hiscock, N., Møller, K., Saltin, B., Febbraio, M. A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021687 · Cited by 767 · cited 2×
“Recently, it has been shown also in humans that intravenous administration of IL-6 causes lipolysis and increased fat oxidation without causing hypertriglyceridaemia [26,56].”
BackgroundMuscle‐derived interleukin‐6: possible biological effects
Pedersen, B. K., Steensberg, A., & Schjerling, P. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0329c.xd · Cited by 599 · cited 1×
“It is secreted from adipose tissue during rest and at high levels from muscle cells during strenuous exercise, even in the absence of muscle damage [4,5].”
BackgroundKeller, C., Steensberg, A., Pilegaard, H., Osada, T., Saltin, B., Pedersen, B. K., & Neufer, P. D. (2001) · The FASEB Journal · doi:10.1096/fj.01-0507fje · Cited by 514
Penetration of interleukin-6 across the murine blood-brain barrier
Banks, W. A., Kastin, A. J., & Gutierrez, E. G. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90933-4 · Cited by 485 · cited 1×
“In mice, IL-6 is to some extent transported over the blood–brain barrier, but this transport seems to be of relatively low magnitude [72].”
BackgroundMedicinal strategies in the treatment of obesity
Bray, G. A., & Tartaglia, L. A. (2000) · Nature · doi:10.1038/35007544 · Cited by 432 · cited 1×
“CNTF has previously been demonstrated to decrease obesity in both dietinduced and genetically obese (ob/ob, db/db) mice [12,13], and the modified form (Axokine) has led to substantial weight loss in obese humans in short-term clinical Phase II studies [14].”
BackgroundAssociation between adiponectin and mediators of inflammation in obese women
Engeli, S., Feldpausch, M., Gorzelniak, K., Hartwig, F., Heintze, U., Janke, J., Möhlig, M., Pfeiffer, A. F. H., Luft, F. C., & Sharma, A. M. (2003) · Diabetes · doi:10.2337/diabetes.52.4.942 · Cited by 422 · cited 1×
“In humans, plasma IL-6 levels were found to be inversely correlated with adiponectin gene expression in fat and/or adiponectin plasma levels [62,63], although in one of these studies this was largely found to be dependent on the clustering of obesity-associated variables [63].”
BackgroundDose-Dependent Effects of Recombinant Human Interleukin-6 on Glucose Regulation
Tsigos, C., Papanicolaou, D. A., Kyrou, I., Defensor, R., Mitsiadis, C. S., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4422 · Cited by 324 · cited 1×
“There is also one report that treatment with higher doses of IL-6 was associated with higher blood glucose levels than low doses in healthy volunteers, although this report is flawed by the lack of vehicle-treated controls [59].”
Tsigos, C., Papanicolaou, D. A., Defensor, R., Mitsiadis, C. S., Kyrou, I., & Chrousos, G. P. (2008) · Neuroendocrinology · doi:10.1159/000127219 · Cited by 223 · cited 3×
“The authors and others have reported that IL-6 stimulates energy expenditure in experimental animals [7,49] and in humans [50,58].”
BackgroundSteensberg, A., Fischer, C. P., Sacchetti, M., Keller, C., Osada, T., Schjerling, P., van Hall, G., Febbraio, M. A., & Pedersen, B. K. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.032938 · Cited by 152
Fasshauer, M., Klein, J., Lossner, U., & Paschke, R. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-39075 · Cited by 151
Cited by
Pro-inflammatory cytokines: The link between obesity and osteoarthritis
Wang, T., & He, C. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.002 · Cited by 1,034
Kristiansen, O. P., & Mandrup-Poulsen, T. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s114 · Cited by 524
Petersen, E. W., Carey, A. L., Sacchetti, M., Steinberg, G. R., Macaulay, S. L., Febbraio, M. A., & Pedersen, B. K. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00257.2004 · Cited by 311
Inflammatory Process in Type 2 Diabetes: The Role of Cytokines
ALEXANDRAKI, K., PIPERI, C., KALOFOUTIS, C., SINGH, J., ALAVERAS, A., & KALOFOUTIS, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1372.039 · Cited by 309
IL-6 selectively stimulates fat metabolism in human skeletal muscle
Wolsk, E., Mygind, H., Grøndahl, T. S., Pedersen, B. K., & van Hall, G. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00328.2010 · Cited by 221
Metadata
- Authors
- Wallenius, K., Jansson, J.-O., & Wallenius, V.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2003-10
- Volume
- 3
- Issue
- 7
- Pages
- 1061-1070
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2054606144
- Cited by
- 42
- References
- 25
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.